Corelogic Inc. (CLGX: Quote) is rising over 4 percent to $18.21. The company's raised its full year 2012 guidance citing higher forecasted mortgage originations, successful execution of Project 30 cost initiatives and margin expansion in the Mortgage Origination Services and Data and Analytics segments.
News Corp. (NWSA: Quote) is down 1 percent to $22.06. The company announced that its board has authorized its plan of separation of publishing and media and entertainment businesses into two distinct publicly traded companies. News Corp.'s shareholders would receive one common share in the new company for each same class company share currently held. Rupert Murdoch would be the Chairman of both companies and CEO of the media and entertainment company.
Synta Pharmaceuticals Corp. (SNTA: Quote) is down more than 26 percent to $5.35. The company reported results from a planned interim analysis of the GALAXY trial designed to evaluate the efficacy and safety of Hsp90 inhibitor, ganetespib, in combination with standard-of-care docetaxel vs. docetaxel alone as second-line treatment for advanced non-small cell lung cancer.
Family Dollar Stores, Inc. (FDO: Quote) is down over 7 percent to $63.75. The company's third quarter profit and sales improved from the year-ago quarter, but missed the analysts' expectations by a whisker.
Curtiss-Wright Corp. (CW: Quote) is falling 7 percent to $28.50. The company lowered its second quarter earnings outlook to reflect the impact of accelerating certain charges associated with restructuring within the Metal Treatment segment, as well as unanticipated additional China AP1000 investments. The company also reduced its full-year earnings guidance as a result of the AP1000 investments.
QUALCOMM, Inc. (QCOM: Quote) is down nearly 1 percent to $54.45. The company announced its plan to modify its corporate structure. The new corporate structure will feature the parent company, Qualcomm Inc., which includes QTL and corporate functions, as well as most of its patent portfolio; and a new wholly owned subsidiary, Qualcomm Technologies, Inc., which will operate substantially all of research and development activities, as well as product and services businesses, including its semiconductor business, QCT.
Vertex Pharmaceuticals Inc. (VRTX: Quote) is down nearly 12 percent to $53.99. The company announced final data from a Phase 2 study of VX-809 and KALYDECO that showed statistically significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene, F508del.
| || |
| To receive FREE breaking news email alerts for Family Dollar Stores and others in your portfolio|
by RTT Staff Writer
For comments and feedback: email@example.com